Aspire Biopharma Holdings, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ASBP Nasdaq 2830 aspirebiolabs.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Aspire Biopharma Holdings, Inc.

Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Ondansetron (Generic Zofran(R)) - Feb 12th, 2026 6:00 am
Aspire Biopharma Announces $21 Million Private Placement by Select Investors, Strengthening Balance Sheet, Capital Position, and Fortifying Shareholder Equity to Meet Nasdaq Requirements - Feb 11th, 2026 5:45 am
Aspire Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement - Feb 10th, 2026 6:00 am
Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, to Showcase BUZZ BOMB(TM) Caffeine and its Innovative Sublingual Delivery Technology at The Sports & Active Nutrition Summit - Feb 5th, 2026 6:00 am
Aspire Biopharma’s Buzz Bomb partners with Blue Shark Beverages - Feb 4th, 2026 6:45 am
Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, Partners with Blue Shark Beverages to Expand Southern California Distribution - Feb 3rd, 2026 6:00 am
Aspire Biopharma Secures Agreement with Microsize for Development of Novel Sublingual Aspirin - Jan 29th, 2026 6:00 am
Aspire files patent application for clopidogrel sublingual powder formulation - Jan 28th, 2026 6:26 am
Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Powder Formulation of Clopidogrel (Generic Plavix(R)) to Address Gastric Bleeding Risks - Jan 27th, 2026 6:00 am
Aspire Biopharma Scales Consumer Division with Delivery of Two Million BUZZ BOMB(TM) Units Featuring Modernized Brand Identity - Jan 22nd, 2026 6:00 am
Aspire Biopharma's Unveils Bold New Era for BUZZ BOMB(TM) Caffeine with Dynamic Website and Packaging Redesign - Jan 21st, 2026 6:00 am
Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Formulation of Alprazolam - Generic Xanax(R) - for Rapid Anxiety Relief - Jan 20th, 2026 6:00 am
BC-Most Active Stocks - Jan 14th, 2026 8:30 am
Aspire Biopharma Announces Reverse Stock Split - Jan 14th, 2026 6:00 am
Aspire Biopharma Announces Successful Pre-IND Meeting with FDA for High-Dose Sublingual Aspirin (OTASA) - Jan 7th, 2026 6:00 am
Aspire Biopharma Welcomes Elite Ultra-Runner Ashley Paulson as Global Brand Ambassador for BUZZ BOMB(R) Caffeine - Dec 18th, 2025 6:30 am
Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements - Dec 12th, 2025 3:00 pm
Aspire Biopharma Provides Q3 2025 Business Update - Dec 4th, 2025 7:00 am
Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack) - Dec 2nd, 2025 7:00 am
Aspire BioPharma Welcomes Dr. Mark J. Jaroszeski as New Scientific Team Member - Nov 26th, 2025 7:00 am